Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.
Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page
- Check8 days agoChange DetectedOnly minor visual/layout adjustments were observed; no core study information such as the title, brief summary, inclusion/exclusion criteria, endpoints, or locations appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedUpgrade to version v3.2.0 with a new government-operating-status notice and links; removes the old v3.1.0 reference.SummaryDifference2%
- Check36 days agoChange DetectedAdded Melanoma genetics topic and updated version from v3.0.2 to v3.1.0.SummaryDifference0.2%
- Check43 days agoChange DetectedAdded a new scientific reference about melanoma treatment; removed a MedlinePlus Genetics related topic on melanoma.SummaryDifference2%
- Check51 days agoChange DetectedThe core trial purpose wording was clarified to compare relatlimab+nivolumab with nivolumab monotherapy; an EU CT Number was added and the old EudraCT Number replaced, along with a new MedlinePlus link and updated revision/date stamps.SummaryDifference1%
- Check58 days agoChange DetectedThe page has been updated to version 3.0.1, and the section on Melanoma related topics from MedlinePlus Genetics has been removed.SummaryDifference0.3%
Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.